These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36907614)
21. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development. Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404 [TBL] [Abstract][Full Text] [Related]
22. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model. Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118 [TBL] [Abstract][Full Text] [Related]
23. Alpha- and Beta-thalassemia: Rapid Evidence Review. Baird DC; Batten SH; Sparks SK Am Fam Physician; 2022 Mar; 105(3):272-280. PubMed ID: 35289581 [TBL] [Abstract][Full Text] [Related]
24. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major. Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543 [TBL] [Abstract][Full Text] [Related]
31. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Gardenghi S; Grady RW; Rivella S Hematol Oncol Clin North Am; 2010 Dec; 24(6):1089-107. PubMed ID: 21075282 [TBL] [Abstract][Full Text] [Related]
32. Pathophysiology of beta thalassemia--a guide to molecular therapies. Thein SL Hematology Am Soc Hematol Educ Program; 2005; ():31-7. PubMed ID: 16304356 [TBL] [Abstract][Full Text] [Related]
34. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Cappellini MD; Musallam KM; Taher AT Hemoglobin; 2009; 33 Suppl 1():S145-59. PubMed ID: 20001620 [TBL] [Abstract][Full Text] [Related]
35. [Research progress of iron metabolism in phenotype modification of β-thalassemia]. Chen D; Sun X Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):27-31. PubMed ID: 33423253 [TBL] [Abstract][Full Text] [Related]
36. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Cappellini MD; Porter JB; Viprakasit V; Taher AT Blood Rev; 2018 Jul; 32(4):300-311. PubMed ID: 29455932 [TBL] [Abstract][Full Text] [Related]
37. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. Jones E; Pasricha SR; Allen A; Evans P; Fisher CA; Wray K; Premawardhena A; Bandara D; Perera A; Webster C; Sturges P; Olivieri NF; St Pierre T; Armitage AE; Porter JB; Weatherall DJ; Drakesmith H Blood; 2015 Jan; 125(5):873-80. PubMed ID: 25519750 [TBL] [Abstract][Full Text] [Related]
38. Pathogenic Mechanisms in Thalassemia I: Ineffective Erythropoiesis and Hypercoagulability. Bou-Fakhredin R; Rivella S; Cappellini MD; Taher AT Hematol Oncol Clin North Am; 2023 Apr; 37(2):341-351. PubMed ID: 36907607 [TBL] [Abstract][Full Text] [Related]
39. Pathogenic Mechanisms in Thalassemia II: Iron Overload. Ganz T; Nemeth E Hematol Oncol Clin North Am; 2023 Apr; 37(2):353-363. PubMed ID: 36907608 [TBL] [Abstract][Full Text] [Related]
40. Cardiac complications in thalassemia throughout the lifespan: Victories and challenges. Wood JC Ann N Y Acad Sci; 2023 Dec; 1530(1):64-73. PubMed ID: 37902424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]